Publicacions en col·laboració amb investigadors/es de Medical University of Lodz (13)

2024

  1. European pollen reanalysis, 1980-2022, for alder, birch, and olive

    Scientific data, Vol. 11, Núm. 1, pp. 1082

  2. Global Framework for Scientific Event: A 32-Country & 118-Expert Collaborative Effort

    Barw Medical Journal, Vol. 2, Núm. 3, pp. 29-39

2023

  1. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70

  2. Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine

    The Lancet Oncology

2022

  1. COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction

    Heart (British Cardiac Society), Vol. 108, Núm. 6, pp. 458-466

  2. Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war

    The Lancet Haematology

  3. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

2021

  1. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 9, pp. 1264-1274

2020

  1. Should breast reconstruction and breast oncoplastic procedures be performed during the coronavirus pandemic?

    ecancermedicalscience, Vol. 14

2019

  1. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794

2014

  1. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

    Blood, Vol. 123, Núm. 26, pp. 4136-4142

2011

  1. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial

    British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051